Unless this copy has been taken directly from the Trust intranet site (Pandora) there is no assurance that this is the most up to date version
|
|
- Emil Horn
- 5 years ago
- Views:
Transcription
1 Policy No: RM80 Version: 3.0 Name of policy: Policy for the Rapid Tranquilisation (RT) of Adult Patients Displaying Acutely Disturbed or Violent Behaviour Effective from: 11/06/2018 Date ratified 06/04/2018 Ratified Safeguarding Committee Review date 01/04/2020 Sponsor Director of Nursing, Midwifery & Quality Expiry date 05/04/2021 Withdrawn date Unless this copy has been taken directly from the Trust intranet site (Pandora) there is no assurance that this is the most up to date version This policy supersedes all previous issues Displaying Acutely Disturbed or Violent Behaviour v3
2 Version control Version Release Author/Reviewer Ratified by/authorised by Date Changes (Please identify page no.) /05/2014 Dr C Kirkley, Old Age Psychiatry /12/2016 Joanne Coleman Strategic Safeguarding Lead /06/2018 Joanne Coleman Strategic Safeguarding Lead SafeCare Council Safeguarding Committee Safeguarding Committee 09/04/ /12/ /04/2018 Standard operating procedure for completion of Datix Displaying Acutely Disturbed or Violent Behaviour v3 2
3 Contents Page No. 1. Introduction Policy scope Aim of policy Duties - roles and responsibilities Definition of terms Rapid tranquilisation (RT) of Adult patients displaying acutely disturbed or violent behaviour What is RT? What is not RT? Key priorities... 6 Algorithm 1 (overview)... 8 Reporting Prediction Medication Mental Health Act Patient monitoring Medical Specific Risks Algorithm 2 (RT in under 65s) Algorithm 3 (RT in over 65s) Consultant advice Standard doses Further (specialist) Treatments Intravenous Therapy Training Diversity and inclusion Monitoring compliance with the policy Consultation and review of this policy Implementation of this policy References Associated documentation Appendix 1 Physical health monitoring and remedial measures Appendix 2 Guidelines for use of Flumazenil Appendix 3 Shortage of Lorazepam injection alternative agents and management options Appendix 4 Rapid tranquilisation in pregnant women Appendix 5 Standard operating procedure for reporting in DATIX 24 Displaying Acutely Disturbed or Violent Behaviour v3 3
4 Policy for the Rapid Tranquilisation (RT) of Adult Patients Displaying Acutely Disturbed or Violent Behaviour 1. Introduction The Trust recognises the importance of good practice in preventing and managing aggressive, violent and potentially violent incidents. Potential behaviour problems should be identified, planned for and defused. However, severe behavioural disturbances will sometimes happen despite all attempts to prevent them. It may become necessary to use pharmacological interventions alongside physical restraint to maintain the safety and physical health of an individual. The administration of medicines under restraint to maintain safety is Rapid Tranquillisation (RT) 2. Policy scope This policy covers all healthcare staff working within inpatient and outpatient settings where RT may be utilised. 3. Aim of policy The aim of this policy is to minimise risk related to the use of RT, ensuring a standard approach to care, based on the best available evidence. The guidance is developed to comply with relevant local and national standards. 4. Duties, roles and responsibilities Trust Board The Trust Board has responsibility for ensuring that a safe and effective policy is in place for RT and that training and facilities are available to support the implementation of the policy. Chief Executive Has responsibility for ensuring the trust has robust and effective policies relating to rapid tranquilisation. Mental Health Committee The Mental Health Committee will be responsible for monitoring the appropriate use and patient monitoring following RT. Safeguarding Lead The Safeguarding lead will be responsible for the regular audit of incidents of RT. Pharmacy Services Provide drug information and advice as required to both staff and patients. Ensure medication to treat disturbed behaviour is available. Displaying Acutely Disturbed or Violent Behaviour v3 4
5 Associate Directors /Service Line Managers Ensure within their area of responsibility the application of the rapid tranquillisation policy is adhered to and where necessary take action to ensure compliance. Medical Staff Ensure they are familiar with the policy and adhere to the protocols and procedures. Ensure that an assessment of the patient s physical health is carried out before prescribing and administrating any medication. Complete all relevant RT documentation, update the current medication chart and ensure nurse in charge is fully aware of any decisions regarding medication. The Ward/Department Sister/Charge Nurse Will be fully aware of the contents of this policy and will ensure that all staff in their ward/department are aware of this policy and other policies and guidance which relate to this policy. Ensure that de-escalation methods are tried first and that any incident of RT is fully documented and reported accordingly. Registered Nurses Will ensure they are aware of the policy and adhere to the protocols and procedures and will ensure they attend all relevant training. Security Staff Security staff will support nursing and medical teams in the management of violent/ aggressive behaviour. 5. Definition of terms Rapid Tranquilisation is a reactive management strategy and typically involves physical intervention. It is the administration of medication to calm or sedate an agitated, violent or aggressive patient as quickly as is safely possible: not to treat the individual s underlying condition. Parenteral medication involves administration of medication either via Intramuscular (IM) or Intravenous (IV) routes. IM (intramuscular) is the injection of drugs directly into the muscle. IV (intravenous) is administration of a drug or substance directly into the vein. Advance Decision is an advance refusal of specific medical treatment to be taken into account and adhered to when a person loses the capacity to make the refusal contemporaneously as defined by the Mental Capacity Act An Advanced Decision relating to medical treatment for mental health disorder may be overruled by Part IV of the Mental Health Act Neuroleptic malignant syndrome (NMS) is caused almost exclusively by the use of antipsychotic medication. Rapid and large increases in dosage, such as rapid tranquillisation, can also trigger the development of NMS. Signs and symptoms include Displaying Acutely Disturbed or Violent Behaviour v3 5
6 muscular rigidity, pyrexia and confusion; sometimes muscle tremors and a sore throat. If NMS occurs it should be treated as a medical emergency. 6. Rapid tranquilisation (RT) of adult patients displaying acutely disturbed or violent behaviours 6.1 What is RT? RT is a reactive management strategy and typically involves physical intervention Clinical judgement may be required to distinguish between what is RT and what is administration of as required medical (PRN) within the following definitions RT is the administration of medication to calm or sedate an agitated, violent or aggressive patient as quickly as is safely possible; not to treat the individuals underlying condition The highly aroused condition of the patient during RT may intensify the effect of medicine used. Patients physical health must be monitored after administration (see para 6.7) 6.2 What is not RT? If medication is used proactively as an intervention to prevent a violent or aggressive incident this is not RT. Some patients may have a care plan which required a prescribed medication (usually on an as required (PRN) basis) to be given to prevent them from becoming violent or aggressive this is not RT 6.3 Key Priorities Drugs for rapid tranquillisation, particularly in the context of restraint, should be used with caution because of the following risks:- Loss of airway Loss of consciousness instead of sedation Respiratory depression or cardiac arrest Over sedation with loss of alertness Cardiovascular collapse Seizures Adverse effects, for example, neuroleptic malignant syndrome Interactions with medication (prescribed or illicit) Underlying coincidental physical disorders If parenteral (IM or IV) proves necessary then the IM route is preferred over IV from a safety point of view. The service user should be transferred to oral routes of administration at the safest opportunity. Displaying Acutely Disturbed or Violent Behaviour v3 6
7 6.3.3 Sufficient time should be allowed for clinical response between IM doses of medications The use of two drugs of the same class for the purpose of RT is not recommended Medications should never be mixed in the same syringe When using IM Haloperidol as a means of managing disturbed/violent behaviour, an antimuscarinic agent such as Procyclidine should be immediately available to reduce the risk of dystonia and other extrapyramidal side effects. This should be given as per manufacturers recommendations IV administration of Diazepam should not be used (due to the high risk of respiratory depression) except in exceptional circumstances, which should be specified and recorded Rapid tranquilisation should only be considered once de-escalation and other strategies have failed to calm the patient. The intervention (along with physical intervention) should be considered a management strategy and not be regarded as a primary treatment technique. When determining which intervention to employ, clinical need, the safety of service users and others and, where possible, any advance decisions should be taken into account. The intervention selected must be a reasonable and proportionate response to the risk posed by the patient at that particular time; this follows guidance given under the Mental Capacity Act The reasons for using Rapid Tranquilisation (and any other intervention) must be explained to the patient at the earliest opportunity Resuscitation In the event of a need for resuscitation in Cragside or Sunniside - dial 999 for attendance by the ambulance service For all other areas within the trust where rapid tranquilisation might be used a crash trolley must be available. Equipment available must include an automatic external defibrillator, a bag valve mask, oxygen and suction equipment. All equipment must be properly maintained and checked as discussed in the Trust Resuscitation policy RM27a All prescribers and staff involved in rapid tranquilisation must be familiar with and have access to the Trust Resuscitation Policy RM27a Any incident requiring rapid tranquilisation (or physical intervention or seclusion) must be contemporaneously recorded. All appropriate staff should be trained to ensure that they are aware of how to correctly record any incident using the appropriate documentation. Displaying Acutely Disturbed or Violent Behaviour v3 7
8 All events of rapid tranquilisation must be reported as an incident on the Datix Incident Reporting system see appendix 5 for standard operating procedure A post-incident review should take place as soon as possible and at least within 72 hours of an incident ending. Wherever possible, a person not directly involved in the incident should lead the review. The review should address the following factors: What happened during the incident? Trigger factors. Each person s role in the incident. Their feelings at the time of the incident, at the review and how they may feel in the near future. What can be done to address their concerns? Legal considerations: When considering RT it is essential that the clinician is clear under what legal authority the treatment will be administered. Legal authority could come from either the capable/ competent patient s valid consent (common law) or the Mental Health Act (see section 6.6). Alternatively, the Mental Capacity Act, if there is reasonable belief that the patient lacks capacity and that there is reasonable evidence that the treatment is in the patient s best interests then the Mental Capacity Act can be used. Any restraint required should be proportionate and necessary to prevent harm to the patient. The entry made into the patient s notes should make it clear which authority was used at the time of RT If a patient has underlying alcohol dependency & has alcohol withdrawal symptoms please refer to the Alcohol pathway policy & detoxification guideline 2011 Displaying Acutely Disturbed or Violent Behaviour v3 8
9 Algorithm 1 Overview algorithm for the short-term management of disturbed/violent behaviour PREDICTION Risk assessment Searching Continuous risk reassessment and use of de-escalation techniques PREVENTION De-escalation techniques Observation INTERVENTIONS FOR CONTINUED MANAGEMENT Consider, in addition to above, one or more of the following Rapid Tranquilisation Seclusion Physical Intervention Used to avoid prolonged physical intervention Use to avoid prolonged physical intervention Medication is required to calm a psychotic or non-psychotic behaviourally disturbed service user When service user has taken previous medication CONTRA-INDICATED AS AN INTERVENTION Should be terminated when rapid tranquillisation, if given, has taken effect When other interventions not yet explored Better if service user responds quickly Can be used to enable rapid tranquillisation to take effect Prolonged physical intervention POST-INCIDENT REVIEW Reference: The short-term management of disturbed/violent behaviour in psychiatric in-patient settings and emergency departments. (National Institute for Clinical Excellence February 2005) Displaying Acutely Disturbed or Violent Behaviour v3 9
10 6.4 Prediction Certain factors can indicate an increased risk of aggressive or physically violent behaviour. A comprehensive clinical risk assessment must be completed including demographic or personal history, clinical and situational variable. A risk management plan must be developed on admission if it is felt there may be the need for RT. This management plan, where possible, should be agreed with the patient and their carer s, friends and/or relative. Employing RT should only be considered once de-escalation and other strategies have failed in line with the Physical Control and Restraint Policy (RM73) 6.5 Medication Treatment Aims Doses To reduce suffering for the patient: psychological or physical (through self-harm or accidents). To reduce risk of harm to others by maintaining a safe environment. To do no harm (by prescribing safe regimes and monitoring physical health). It is recognised that clinicians may decide that the use of medication outside of the Summary of Product Characteristics (SPC) is occasionally justified, bearing in mind the overall risks. However, where the regulatory authorities or manufacturer issues specific warning that this may result in an increased risk of fatality, the medication should only be used strictly in accordance with the current marketing authorisation. In certain circumstances, current British National Formulary (BNF) uses and limits, and the manufacturers SPC, may be knowingly exceeded e.g. Lorazepam. This decision should not be taken lightly or the risks underestimated, and a risk-benefit analysis should be recorded in the case notes and a rationale in the care plan. Where the risk-benefit is unclear, consideration should be given to seeking advice from clinicians who are not directly involved in the care of the patient. If current BNF doses or SPC are exceeded it is particularly important to undertake frequent and intensive monitoring of a calmed patient. Particular attention must be given to regular checks of the airway, level of consciousness, pulse, blood pressure, respiratory effort, temperature and hydration. Doses of medication should be individualised for each patient. This will be dependent on several factors including the patient s age (older patients will generally require lower doses), concomitant physical disorders (e.g. renal, Protocol/Policy for the Rapid Tranquillisation (RT) of Patients Displaying Acutely Disturbed or Violent Behaviour version 1
11 6.6 Mental Health Act hepatic, cardiovascular, neurological), and concomitant medication. Particular attention must be given to any psychotropic medication administered to the patient in the past 24 hours and how rapid tranquilisation treatment might need to be adjusted as a result Discontinuation Rapid tranquilisation should be discontinued at the point of response. Thereafter, the patient must continue to be closely monitored, and future medication (both regular and as required) should be reviewed. Patients detained under the Mental Health Act are subject to consent to Treatment (MHA part 4). If they have been detained for more than 3 months, they will require consent under Section 58 (3) with a current T2 or T3 form, or be treated under Section 62 urgent treatment to prevent harm to self or others. All information relevant to MHA status must be fully documented in the medical notes. The patients legal status should be reviewed whenever parenteral medication is considered. The enforced administration of medication by injection in an informal patient may necessitate use of the Mental Health Act 6.7 Patient Monitoring Where possible, baseline measurements of the following should be recorded before any parenteral drug administration: - Temperature - Pulse - Respiratory Rate - Blood Pressure The measurements above must also be recorded every 5 10 minutes for 1 hour following the parenteral administration of any drug. Thereafter, they should be recorded at the half hourly intervals until the patient is fully ambulatory. In addition, staff should closely monitor for signs of extra-pyramidal side effects in response to the administration of antipsychotic medication. The patient must be monitored by within eyesight observation. Where the patient is unconscious or asleep, the same monitoring should take place so far as is possible, and pulse-oximetry should also be used. Where possible, and where facilities exist, ECG and haematological monitoring are also strongly recommended when parenteral anti-psychotics are administered, 11
12 especially where high doses have been used. High stress levels, agitation, and hypokalemia all place the patient at high risk of developing cardiac arrhythmias. The observations must be recorded on the EWS chart. Ref. Enhanced Care Policy and Supportive Engagement (observation) (Related to Mental Health & Advanced Physical Care) 6.8 Medication Specific Risks There are specific risks with different classes of medication and these risks may be compounded when medication is used in combination. Close monitoring of the patient is essential. Benzodiazepines Loss of Consciousness, Respiratory Depression or Cardiac Arrest, Cardiovascular Collapse (particularly in Clozapine patients). Antipsychotics Loss of Consciousness, Cardiovascular / respiratory complications and collapse, seizures, akathisia, Dystonia, Dyskinesia, neuroleptics malignant syndrome, excessive sedation. 12
13 Rapid Tranquilisation of the Acutely Disturbed / Violent Patient Under 65s Algorithm 2 Step 1 NON-PHARMACOLOGICAL MEASURES De-escalation, distraction, seclusion etc Consult any Advance Directives Step 2 Oral Treatment [a, b] Lorazepam 1 2mg 1 st line, non psychotic context or if already prescribed regular antipsychotics and/or Olanzapine 10mg Or Haloperidol 5mg If psychotic context ALLOW AT LEAST 45 MINUTES FOR ORAL MEDICATION TO WORK IF INEFFECTIVE, REPEAT ORAL MEDICATION AT SAME DOSES ALLOW AT LEAST 45 MINUTES FOR REPEATED ORAL MEDICATION TO WORK IF ORAL MEDICATION IS REFUSED CONSIDER COVERT ADMINISTRATION Prior to proceeding to step 3 (i/m treatment) consider using Buccal Midazolam 10 20mg (Unlicensed) Step 3 I/M Treatment [c, d] Ensure baseline measurements are recorded on the EWS chart: TEMPERATURE, PULSE, BP, RESPIRATORY RATE before IM administration, and repeat every 5-10 minutes for 1 hour, then half-hourly until patient is ambulatory. Use pulse oximetry if patient asleep or unconscious. MONITOR PATIENT CLOSELY! Lorazepam 1-2mg I/M [d][e] 1 st line non psychotic context AND and /or [b] Haloperidol 5mg I/M [f] ALLOW AT LEAST 30 MINUTES FOR I/M HALOPERIDOL and/or I/M LORAZEPAM TO WORK. IF INEFFECTIVE, REPEAT AT SAME DOSES AND ALLOW A FURTHER 30 MINUTES FOR EFFECT. DO NOT PROCEED FURTHER WITHOUT ADVICE FROM CONSULTANT (see Section 6.9) IF INEFFECTIVE, SEEK SPECIALIST ADVICE FROM CONSULTANT 13
14 Notes for Algorithm 2 a. Choice depends on current treatment. It patient is established on antipsychotics, Lorazepam may be used alone. If the patient uses street drugs or already receives regular benzodiazepines, an antipsychotic may be used alone. For the majority of patients, best response will be with combination therapy. b. Ensure Procyclidine injection is available. Antipsychotic may cause acute dystonic reaction. c. As in (a), either antipsychotic or benzodiazepine may be used alone, but best results are likely with combination therapy. d. Ensure Flumazenil injection is available to reverse effects of Lorazepam injection. e. Lorazepam should be mixed 1:1 with water before injecting. Shortage of Lorazepam injection see Appendix 3. f. Haloperidol (5mg) can also be used but should be the last drug considered because of the relatively high incidence of acute Dystonia and the recommendation that patients should have a pre-treatment ECG & IM Procyclidine available. 14
15 Algorithm 3 Rapid Tranquilisation of the Acutely Disturbed / Violent Patient - Patient Aged Over 65 Years - Step 1 NON-PHARMACOLOGICAL MEASURES De-escalation, distraction, seclusion etc Consult any advance directives Step 2 Oral Treatment [a,b] Lorazepam 0.5-1mg 1 st line, non psychotic context or if already prescribed regular antipsychotics AND/OR Olanzapine 2.5-5mg Haloperidol mg (Unless previously tolerated higher doses ) In patients with Parkinson s disease or dementia, especially those with a history of vascular disease or Lewey body dementia, antipsychotics should be used with caution or not at all. [b, f] ALLOW AT LEAST 45 MINUTES FOR ORAL MEDICATION TO WORK IF INEFFECTIVE, REPEAT ORAL MEDICATION AT SAME DOSES ALLOW AT LEAST 45 MINUTES FOR REPEATED ORAL MEDICATION TO WORK IF ORAL MEDICATION IS REFUSED CONSIDER COVERT ADMINISTRATION Prior to proceeding to step 3 (i/m treatment) consider using Buccal Midazolam 10 20mg (Unlicensed) Step 3 I/M Treatment [c,d] Ensure baseline measurements are recorded on the EWS chart: TEMPERATURE, PULSE, BP, RESPIRATORY RATE before IM administration, and repeat every 5-10 minutes for 1 hour, then half-hourly until patient is ambulatory. Use pulse oximetry if patient asleep or unconscious. MONITOR PATIENT CLOSELY! Lorazepam 1-2mg I/M [d] [e] 1 st line non psychotic context AND/ AND/ OR Haloperidol 1 2.5mg I/M [f] ALLOW AT LEAST 45 MINUTES FOR I/M HALOPERIDOL and/or I/M LORAZEPAM TO WORK. IF INEFFECTIVE, REPEAT AT SAME DOSES AND ALLOW A FURTHER 45 MINUTES FOR EFFECT. DO NOT PROCEED FURTHER WITHOUT ADVICE FROM CONSULTANT (see Section 6.9) IF INEFFECTIVE, SEEK SPECIALIST ADVICE FROM CONSULTANT 15
16 Notes for Algorithm 3: a. Choice depends on current treatment. If patient is established on antipsychotics, Lorazepam may be used alone. If the patient uses street drugs or already receives regular benzodiazepines, an antipsychotic may be used alone. For the majority of patients, best response will be with combination therapy. b. Ensure Procyclidine injection is available. Antipsychotic may cause acute dystonic reaction. c. As in (a), either antipsychotic or benzodiazepine may be used alone, but best results are likely with combination therapy. d. Ensure Flumazenil injection is available to reverse effects of Lorazepam injection. e. Lorazepam should be mixed 1:1 with water before injecting. Shortage of Lorazepam injection see below. f. Haloperidol (5mg) can also be used but should be the last drug considered because of the relatively high incidence of acute Dystonia and the recommendation that patients should have a pre-treatment ECG & IM Procyclidine available. 16
17 6.9 Consultant Advice Advice must be sought from the Consultant, (or Consultant on-call), at any stage of rapid tranquilisation if any doubt exists regarding how best to proceed Standard Doses (BNF) Standard doses of medication used in rapid tranquilisation are listed below. Whenever possible doses prescribed should be within these limits. However, prescribing outside recommended standard doses may occasionally be justified. (See section 6.5.2) Haloperidol: oral = 30mg / 24 hours, I/M = 18mg / 24 hours (i.e. 3mg haloperidol I/M is approximately equivalent to 5mg oral) Lorazepam: oral = 4mg / 24 hours, I/M = 30mcg / kg / 6 hours (i.e. I/M maximum is approximately 6-8mg / 24 hours) Olanzapine: oral = 20 mg/24 hours, this dose should not be exceeded without obtaining specialist advice 6.11 Further (specialist) Treatments The following treatments are rarely used, have a minimal evidence base and are unlicensed. They may only be prescribed by or under guidance of a senior clinician or consultant who has previous experience of their use. Any decision to use these treatments must only be taken when more conventional treatments have failed and must be fully documented in the patient s notes Midazolam I/M Flumazenil must be available Promethazine I/M Can be used in patients who are benzodiazepine tolerant. Slow onset of action but highly sedating Diazepam I/V (Diazemuls) Flumazenil must be available. Produces very rapid response Haloperidol I/V Dose as per I/M route. (see section 6.12) 6.12 Intravenous Therapy The intravenous administration of benzodiazepines or haloperidol should not normally be used except in very exceptional circumstances, which should be specified and recorded. This decision should only be taken by a consultant or senior clinician who has had previous experience of its use. 17
18 7 Training If immediate tranquilisation is essential then intravenous administration may be considered necessary. If so, it is essential that attending staff have been appropriately trained to recognise symptoms of respiratory depression, acute dystonia and cardiovascular compromise If intravenous medication is used, the patient must never be left unattended. Intravenous administration must not take place without full access to support and resuscitation services. 7.1 All staff involved in administering or prescribing rapid tranquilisation, or monitoring patients to whom parenteral rapid tranquilisation has been administered, must receive ongoing competency training to a Trust recognised standard which includes maintenance of airway, cardio-pulmonary resuscitation (CPR), the use of defibrillators, and the use of pulse oximeters. This must include training to ensure that they are aware of how to correctly record any incident using the appropriate documentation. 7.2 All prescribers, and those staff who administer medicines for rapid tranquilisation, should be familiar with and have received training which includes the following The properties of benzodiazepines, the benzodiazepine antagonist flumazenil, antipsychotics, antimuscarinics and antihistamines. Associated risks, including cardio-respiratory effects of the acute administration of the drugs, particularly when the patient is highly aroused and may have been misusing drugs, is dehydrated, or is possibly physically ill. The need to titrate doses to effect. 8 Diversity and Inclusion The Trust is committed to ensuring that, as far as is reasonably practicable, the way we provide services to the public and the way we treat staff reflects their individual needs and does not unlawfully discriminate against individuals or groups on the grounds of any protected characteristic (Equality Act 2010). This policy aims to uphold the right of all staff to be treated fairly and consistently and adopts a human rights approach. This policy has been appropriately assessed. 9 Monitoring compliance with the policy Standard/process/issue Audit of incidents of RT against case notes to ensure appropriate use and monitoring following RT Monitoring and audit Method By Audit of Safeguarding all lead incidents reported on Datix Committee Frequency Mental 6 monthly Health Committee and SafeCare 18
19 10 Consultation and review There has been significant consultation on the policy including the Associate and Divisional Directors, Service Line Managers, Modern Matrons, Medical & Nursing staff within Old Age Psychiatry and Accident & Emergency, CMH Nursing staff, relevant Ward sisters, pharmacy and operational staff. 11 Implementation of policy (including raising awareness) The policy will be implemented in line with OP27 Policy on the Development, implementation and management of policies and through departmental meetings and brought to the attention of relevant staff through team meetings. 12 References 12.1 Violence the short term management of disturbed / violent behaviour in psychiatric in-patient settings and emergency departments. National Institute for clinical Excellence, February The South London and Maudsley NHS Trust and Oxleas NHS Trust Prescribing Guidelines (1oth edition) 12.3 Antenatal and Postnatal mental health. National Institute for Clinical Excellence, February Mental Health Act 1983 Code of Practice 12.5 Mental Capacity Act 2005 Code of Practice 12.6 NICE Clinical Guideline 25 February Associated documentation RM73 Restrictive Interventions Policy RM27a Resuscitation Policy RM04 Incident reporting policy Medicines Management Policy RM32 Policy and Procedure for the Care of Individuals who are Violent or Abusive 19
20 Physical health monitoring and remedial measures Appendix 1 Rapid Tranquilisation monitoring After any parenteral drug administration, monitor the following: Temperature Pulse Blood Pressure Respiratory Rate Every 5 10 minutes, for one hour, then half-hourly until patient is ambulatory. If the patient is asleep or unconscious, the use of pulse oximetry to continuously measure oxygen saturation is desirable. A nurse should remain with the patient until they are ambulatory again and observation should be re-assessed at this stage. ECG and haematological monitoring are also strongly recommended when parenteral antipsychotics are given, especially when higher doses are used. Hypokalaemia, stress, and agitation place the patient at risk of cardiac arrhythmias. Remedial measures in rapid tranquilisation Problem Acute dystonia (Including oculogyric crises) Remedial measures Give Procyclidine 5 10mg IM Reduced respiratory rate Give oxygen; raise legs; ensure patient is not lying face down. (<10/min) or oxygen saturation Give flumazenil if benzodiazepine-induced respiratory depression (<90%) suspected (see Appendix 2). If induced by any other sedative agent, ventilate mechanically. Irregular or slow (<50/min) pulse Fall in blood pressure (>30mmHg orthostatic drop or <50mmHg diastolic) Increased temperature Refer to specialist medical care immediately. Lie patient flat, tilt bed towards head. Monitor closely Withhold antipsychotics (risk of NMS and perhaps arrhythmias). Check creatinine kinase urgently. 20
21 Guidelines for use of Flumazenil Appendix 2 Guidelines for use of flumazenil Indication for use Contra-indications Caution Dose and route of administration Time before dose can be repeated Maximum dose Side effects Management If respiratory rate falls below 10/minute after the administration of Lorazepam, Midazolam or diazepam. Patients with epilepsy who have been receiving long-term benzodiazepines. Dose should be carefully titrated in hepatic impairment. Initial 200mcg intravenously over 15 seconds if required level of consciousness not achieved after 60 seconds the, Subsequent dose: 100mcg over 10 seconds 60 seconds 1mg in 24 hours (one initial dose and eight subsequent doses). Patients may become agitated, anxious or fearful on awakening. Seizures may occur in regular benzodiazepine users. Side effects usually subside. Monitoring What to monitor? Respiratory rate How often? Continuously until respiratory rate returns to baseline level. Flumazenil has a short half life. Respiratory function may recover then deteriorate again. Note: If respiratory rate does not return to normal or patient is not alert after initial doses assume sedation due to some other cause. 21
22 Shortage of Lorazepam injection Alternative agents and management options. Appendix 3 Buccal Midazolam (10-20mg) may be considered initially (although unlicensed) to avoid the need to move on to an intramuscular injection. If oral / buccal treatment is not appropriate, or if two doses fail (with minute gap between doses), consider if antipsychotic therapy is appropriate Haloperidol Adults under 65, 5mg I/M. Adults over 65, 1 2.5mg I/M If a benzodiazepine is indicated Diazepam, (can be painful if given by the intramuscular route). Adults under 65, 10mg I/M, Adults under 65, 5mg I/M. Alternatively Midazolam i.m. can be used. Flumazenil must be available. Adults under 65, mcg / Kg, maximum dose 5mg. Adults over 65, 25 50mcg / Kg usual dose range 1 2.5mg max dose 5mg. Promethazine 25 50mg can be prescribed by or under guidance of a senior clinician or consultant who has had previous experience of its use see section
23 Appendix 4 Rapid Tranquilisation in Pregnant Women A pregnant woman requiring rapid tranquillisation should be treated using the Protocol/Policy for the Rapid Tranquilisation (RT) of Adult Patients Displaying Acutely Disturbed or Violent Behaviour except Do not seclude the woman following rapid tranquillisation. Adapt restraint procedures to avoid possible harm to the foetus. When choosing an agent for rapid tranquillisation, consider an anti psychotic (e.g. haloperidol) or benzodiazepine (e.g. lorazepam) with a shorter half life. If an antipsychotic is used it should be at the minimum effective dose to minimise the risk of neonatal extrapyramidal symptoms. If a benzodiazepine is used the risks of floppy baby syndrome should be taken into account. Manage the woman s care during the perinatal period in close collaboration with a paediatrician and an anaesthetist. Adapted from: NICE clinical guideline 45 Antenatal and postnatal mental health Published: February
24 Appendix 5 Rapid Tranquilisation Due to V&A Rapid Tranquilisation SOP Incident occurs; First step is to report and this incident (see below) and then the date, Datix number and details of the person reporting must be detailed in the relevant patient records. These are the only details needed to avoid duplication as the incident documentation will be added to the patient s notes at the end of the process. All relevant details will be within this documentation. 1) Select the Category & Sub Category of Incident (e.g. assault on staff) 2) Select physical assault requiring control & restraint of patient 3) Select Chemical restraint 4) This will make the Rapid Tranquilisation section appear 24
25 Rapid Tranquilisation Disruptive due to Patients Medical Condition (e.g. 1) Select Category & Sub Category of Incident 2) Complete Rapid Tranquilisation section as step 4 above. Pulling Document from Datix for Medical Notes 25
26 1) Go into the incident and go to the Documents tab 2) Select Rapid Tranquilisation Form from the templates then click generate 3) You will see a pop up saying choose a contact, select the patient then click confirm 4) Click on the generated document and it will open in word, you will now be able to print 5) The document will need to be printed off and added into the relevant Patient records for completeness. 26
Guideline for use of Intramuscular Medication for Acutely Disturbed Behaviour in Mental Health and Associated Services
NHS GGC Mental Health Service Guideline for use of Intramuscular Medication for Acutely Disturbed Behaviour in Mental Health and Associated Services Important Note: The Intranet version of this document
More informationFormulary and Clinical Guideline Document Pharmacy Department Medicines Management Services
Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services VIOLENCE, AGGRESSION OR SEVERE BEHAVIOURAL DISTURBANCE Introduction During an acute episode or illness, some
More informationRapid Tranquillisation for adolescent, adults and older people Medicines management team July 2014
Rapid Tranquillisation for adolescent, adults and older people Medicines management team July 2014 A definition of rapid tranquillisation (RT) The use of medicines to quickly control extreme agitation,
More informationGuidance for Drug Treatment of Acute Behavioural Disturbance (Rapid Tranquillisation)
Guidance for Drug Treatment of Acute Behavioural Disturbance (Rapid Tranquillisation) Author: Endorsing Body: Governance or Assurance Committee Implementation Date: March 2014 Version Number: 1.5 Review
More informationThe Rapid Tranquillization Policy. (including the use of oral PRN medication) (Replaces Policy No. 198/Clinical)
A member of: Association of UK University Hospitals The Rapid Tranquillization Policy. (including the use of oral PRN medication) (Replaces Policy No. 198/Clinical) (The Use of Medication in the Control
More informationRapid Tranquilisation Policy
Rapid Tranquilisation Policy Who Should Read This Policy Target Audience All Inpatient Staff Version 1.1 August 2015 Ref. Contents Page 1.0 Introduction 4 2.0 Purpose 4 3.0 Objectives 4 4.0 Process 4 4.1
More informationEmergency Control of the Acutely Disturbed Adult Patient GUIDELINES ON EMERGENCY CONTROL OF THE ACUTELY DISTURBED ADULT PATIENT... 2 ACTION...
Delirium Toolkit Emergency Control of the Acutely Disturbed Adult Patient Table of Contents GUIDELINES ON EMERGENCY CONTROL OF THE ACUTELY DISTURBED ADULT PATIENT... 2 ACTION... 2 AFTERCARE... 3 NOTES...
More informationThis controlled document shall not be copied in part or whole without the express permission of the author or the author s representative.
This document is also available in large print and other formats and languages, upon request. Please call NHS Grampian Corporate Communications on (01224) 551116 or (01224) 552245. This controlled document
More informationAssessment of physical monitoring following rapid tranquillisation. Stephen Dye
Assessment of physical monitoring following rapid tranquillisation Stephen Dye Aims X Lecture on developments in RT Review of recent studies Discussion of specific medications Containment measures Definition
More informationSiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA. [compatible with NICE guidance]
SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA [compatible with NICE guidance] Medicines Management Committee August 2002 For review August 2003 Rationale The SiGMA algorithm
More informationGuidelines for the use of Zuclopenthixol Acetate (Clopixol Acuphase ) injection. Version 1
Guidelines for the use of Zuclopenthixol Acetate (Clopixol Acuphase ) injection Version 1 SUMMARY Guidelines for the use of Zuclopenthixol Acetate (Clopixol Acuphase ) injection POLICY CODE REPLACES POLICY
More informationMERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES. MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) KEY ISSUES
MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) Medicines Management Services aim to ensure that (i) Service users receive their medicines
More informationGuidance on Consent to Treatment Documentation for Medication Patient s Detained under the Mental Health Act
Guidance on Consent to Treatment Documentation for Medication Patient s Detained under the Mental Health Act This guidance is intended for Coventry and Warwickshire Partnership Trust staff to use when
More informationManagement of Severe Agitation
Management of Severe Agitation Key Points 1. The management of the severely agitated or violent patient embraces psychological, physical and pharmacological approaches. 2. Psychological methods focus on
More informationRapid Tranquilisation and the Management of Violent and Aggressive Paediatric Patients
Rapid Tranquilisation and the Management of Violent and Aggressive Paediatric Patients Version: 1 Approval Committee (eg Clinical network): Date of Approval: Signature of approving Group Chair Ratification
More informationRapid Tranquillisation Policy
Rapid Tranquillisation Policy Rapid Tranquillisation Policy Document Type Clinical Policy Unique Identifier CL-033 Document Purpose To provide advice, support and consistency for staff dealing with psychiatric
More informationGUIDANCE FOR THE USE OF ZUCLOPENTHIXOL ACETATE (CLOPIXOL ACUPHASE) IN ADULTS MAY 2017
GUIDANCE FOR THE USE OF ZUCLOPENTHIXOL ACETATE (CLOPIXOL ACUPHASE) IN ADULTS MAY 2017 This policy supersedes all previous Guidance for the use of clopixol acuphase (zuclopenthixol acetate) in adults. GUIDANCE
More informationPOLICY DOCUMENT. Pharmacy MMG/MPG. Approved By and Date Medicines Management roup March March 2016
POLICY DOCUMENT Document Title High dose and combination antipsychotic guidance Reference Number n/a Policy Type Prescribing and Treatment Guideline Electronic File/Location Clinical Resources/Pharmacy/Prescribing
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Title: Shared Care Guideline for the prescribing and monitoring of Antipsychotics for the treatment of Schizophrenia and psychotic symptoms in children and adolescents Scope: Pennine
More informationDelirium. Quick reference guide. Issue date: July Diagnosis, prevention and management
Issue date: July 2010 Delirium Diagnosis, prevention and management Developed by the National Clinical Guideline Centre for Acute and Chronic Conditions About this booklet This is a quick reference guide
More informationChoosing and delivering ering interventions entions for
Choosing and delivering ering interventions entions for psychosis and schizophrenia in adults bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to
More informationAll in service user areas where RT is likely to be used. Rapid, tranquilisation, inpatient, in-patient, ward
Policy: Rapid Tranquilisation Policy and Guidelines for In-patient Wards Executive or Associate Director lead Policy author/ lead Feedback on implementation to Dr Mike Hunter, Medical Director Chris Hall,
More informationClinical. High Dose Antipsychotic Prescribing Procedures. Document Control Summary. Contents
Clinical High Dose Antipsychotic Prescribing Procedures Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation
More informationManaging Behavioural Problems in Patients with Learning Disabilities
Managing Behavioural Problems in Patients with Learning Disabilities Some people with a learning disability display behaviour that challenges. Although such behaviour is a challenge to services, family
More information28 th September Author Jeremy Gilbert Bariatric Nurse Specialist
POLICY FOR SELF ADMINISTRATION OF CONTINUOUS POSITIVE AIRWAY PRESSURE BY COMPETENT PATIENTS COMING IN FOR METABOLIC AND OBESITY SURGERY (BARIATRIC SURGERY) TO PENDENNIS WARD 28 th September 2014 Author
More informationMental Health Medicines Management Pilot. Community Pharmacy. High Dose Antipsychotic Screening, Education & Advice Service
Mental Health Medicines Management Pilot Community Pharmacy High Dose Antipsychotic Screening, Education & Advice Service Approved Version 1 Date of First Issue Review Date Date of Issue Author / Contact
More informationOlanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015)
1. Key Points Olanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015) 1.1 Olanzapine long acting injection (LAI) is indicated for the maintenance
More informationCritical Care Pharmacological Management of Delirium
Critical Care Pharmacological Management of Delirium Policy Title: in the Critical Care Unit Executive Summary: This policy provides guidance Pharmacological Management of delirium in the Critical Care
More informationInitiation of Clozapine Treatment Community Patients
Initiation of Clozapine Treatment Community Patients Who Should Read This Policy Target Audience All clinical staff working in the community N/A N/A Initiation of Clozapine Treatment for Patients in the
More informationGUIDELINES FOR THE USE OF NALOXONE INJECTION FEBRUARY 2018
GUIDELINES FOR THE USE OF NALOXONE INJECTION FEBRUARY 2018 Guidelines for the use of naloxone injection in acute services Policy title Policy reference PHA58 Policy category Clinical Relevant to All medical,
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
Ongoing care for adults with psychosis or schizophrenia bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly
More informationSECTION 9 : MANAGEMENT OF MOVEMENT DISORDERS AND EXTRAPYRAMIDAL SIDE EFFECTS
SECTION 9 : MANAGEMENT OF MOVEMENT DISORDERS AND EXTRAPYRAMIDAL SIDE EFFECTS Formulary and Prescribing Guidelines 9.1 Introduction Movement disorders and extrapyramidal side effects can manifest in the
More informationDatix Ref:
Title Document Details Shared Care Agreement: Antipsychotics (Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine) Trust Ref No 2081-38933 Local Ref (optional) Main points the document
More informationHIGH DOSE ANTIPSYCHOTIC GUIDELINES (HDAT)
HIGH DOSE ANTIPSYCHOTIC GUIDELINES (HDAT) Document Reference Version Number 2.00 High Dose Antipsychotic Guidelines (HDAT) G376 Author/Lead Job Title Jackie Stark Principal Pharmacist Clinical Services
More informationClinical guideline Published: 23 March 2011 nice.org.uk/guidance/cg120
Coexisting severe ere mental illness (psychosis) and substance misuse: assessment and management in healthcare settings Clinical guideline Published: 23 March 2011 nice.org.uk/guidance/cg120 NICE 2018.
More informationGUIDELINES ON CONSCIOUS SEDATION FOR DENTAL PROCEDURES
AUSTRALIAN AND NEW ZEALAND COLLEGE OF ANAESTHETISTS ABN 82 055 042 852 ROYAL AUSTRALASIAN COLLEGE OF DENTAL SURGEONS ABN 97 343 369 579 Review PS21 (2003) GUIDELINES ON CONSCIOUS SEDATION FOR DENTAL PROCEDURES
More informationKeep Calm and Carry On Management of the Agitated Patient in the ED 29TH ANNUAL UPDATE IN EMERGENCY MEDICINE FEBRUARY 21-24, 2016
Keep Calm and Carry On Management of the Agitated Patient in the ED 29TH ANNUAL UPDATE IN EMERGENCY MEDICINE FEBRUARY 21-24, 2016 Dr. Jeffrey Tyberg Sunnybrook Health Sciences Centre University of Toronto
More informationPsychosis with coexisting substance misuse
Psychosis with coexisting substance misuse Assessment and management in adults and young people Issued: March 2011 NICE clinical guideline 120 guidance.nice.org.uk/cg120 NICE has accredited the process
More informationDeveloped By Name Signature Date
Patient Group Direction 2155 version 2.0 Administration / Supply of Inhaled Salbutamol in Asthma by Registered Practitioners employed by Torbay and South Devon NHS Foundation Trust Date of Introduction:
More informationClinical Guideline for Intravenous Opioids for Adults in Recovery Areas The Recovery Protocol
Clinical Guideline for Intravenous Opioids for Adults in Recovery Areas The Recovery Protocol 1. Aim/Purpose of this Guideline 1.1. To Provide safe and efficient administration of Opioids in Recovery.
More informationHigh Dose Antipsychotic Therapy (HDAT) guideline
Document level: Trustwide (TW) Code: MP18 Issue number: 2 High Dose Antipsychotic Therapy (HDAT) guideline Lead executive Medical Director Author and contact number Lead Clinical Pharmacist 01625 663 857
More informationSedation in Children
CHILDREN S SERVICES Sedation in Children See text for full explanation and drug doses Patient for Sedation Appropriate staffing Resuscitation equipment available Monitoring equipment Patient suitability
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
Recognising and managing bipolar disorder in adults in primary care bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are
More informationVersion Number: 5. Patient Group Direction drawn up by: Chief Pharmacist - Strategy. Group direction authorised by:
PATIENT GROUP DIRECTION (PGD) FOR THE INPATIENT ADMINISTRATION OF ORAL LORAZEPAM TO WORKING AGE AND OLDER PEOPLE (includes persons in a Place of Safety suite) Version Number: 5 Patient Group Direction
More informationCommunity Paediatric Policy for minimal sedation
Community Paediatric Policy for minimal sedation Classification: Policy Lead Author: Amy Wilson Consultant Community Paediatrician Additional author(s): Trust Sedation Comittee Authors Division: Salford
More informationMental Health in STH Mike Richmond, Medical Director Mark Cobb, Clinical Director of Professional Services Debate & Note
SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST EXECUTIVE SUMMARY REPORT TO THE TRUST HEALTHCARE GOVERNANCE COMMITTEE E TO BE HELD ON 27 FEBRUARY 2012 Subject: Supporting Director: Author: Status 1 Mental
More information1.3. A Registration standard for conscious sedation has been adopted by the Dental Board of Australia.
Policy Statement 6.17 Conscious Sedation in Dentistry 1 (Including the ADA Recommended Guidelines for Conscious Sedation in Dentistry and Guidelines for the Administration of Nitrous Oxide Inhalation Sedation
More informationPAIN AND SYMPTOM MANAGEMENT GUIDANCE IN THE LAST DAYS OF LIFE
PAIN AND SYMPTOM MANAGEMENT GUIDANCE IN THE LAST DAYS OF LIFE Reference: DCM029 Version: 1.1 This version issued: 07/06/18 Result of last review: Minor changes Date approved by owner (if applicable): N/A
More informationPRESCRIBING GUIDELINES
The Maudsley The South London and Maudsley NHS Foundation Trust & Oxleas NHS Foundation Trust PRESCRIBING GUIDELINES 10th Edition David Taylor Carol Paton Shitij Kapur informa healthcare Contents Authors
More informationThe licensed indications for the use of Clozapine are:- Treatment resistant schizophrenia.
1. Introduction Future Directions CIC will support the use of the antipsychotic Clozapine in all appropriate cases. The purpose of this procedure is to set out the standards for Clinicians, Pharmacists,
More informationHigh Dose Antipsychotic Medication Policy
High Dose Antipsychotic Medication Policy Policy Title State previous title where relevant State if Policy New or Revised Policy Strand Org, HR, Clinical, H&S, Infection Control, Finance For clinical policies
More informationCritical Care Pharmacological Management of Delirium
Critical Care Pharmacological Management of Delirium Policy Title: in the Critical Care Unit Executive Summary: This policy provides guidance Pharmacological Management of delirium in the Critical Care
More informationpatient group direction
DIAZEPAM (RECTAL) v01 1/8 DIAZEPAM (RECTAL) PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care
More informationPATIENT GROUP DIRECTION (PGD) FOR THE ADMINISTRATION OF ORAL DIAZEPAM TO WORKING AGE AND OLDER PEOPLE IN THE COMMUNITY
PATIENT GROUP DIRECTION (PGD) FOR THE ADMINISTRATION OF ORAL DIAZEPAM TO WORKING AGE AND OLDER PEOPLE IN THE COMMUNITY Version Number: 5 Patient Group Direction drawn up by: Name Ray Lyon Dr Al Amaladoss
More informationPsychosis with coexisting substance misuse. Assessment and management in adults and young people
Issue date: March 2011 Psychosis with coexisting substance misuse Assessment and management in adults and young people NICE clinical guideline 120 Developed by the National Collaborating Centre for Mental
More informationGuideline for the Identification and Management of Delirium (Including use of the THINK DELIRIUM Support Tool)
Guideline for the Identification and Management of Delirium (Including use of the THINK DELIRIUM Support Tool) B27/2009 1. Introduction 1.1 Delirium is a common problem which occurs in about 15-20 out
More informationpatient group direction
DIAZEPAM v01 1/9 DIAZEPAM PGD Details Version 1.0 Legal category Staff grades Approved by CD Benz POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner
More informationFalls The Assessment, Prevention and Management of Patient Falls (Adult Services) 1.34
SECTION: 1 PATIENT CARE Including Physical Healthcare POLICY /PROCEDURE: 1.34 NATURE AND SCOPE: SUBJECT (Title): POLICY AND PROCEDURE - TRUST WIDE FALLS: THE ASSESSMENT, PREVENTION AND MANAGEMENT OF PATIENT
More informationMMG003 GUIDELINES FOR THE USE OF HYPNOTICS FOR THE TREATMENT OF INSOMNIA
MMG003 GUIDELINES FOR THE USE OF HYPNOTICS FOR THE TREATMENT OF INSOMNIA Page 1 of 11 Table of Contents Why we need this Guideline... 3 What the Policy is trying to do... 3 Which stakeholders have been
More informationconcentrate intravenous solution and other strong potassium solutions
Policy for the use of potassium chloride concentrate intravenous solution and other strong potassium solutions CLINICAL GUIDELINES ID TAG Policy for the use of potassium chloride Title: concentrate intravenous
More informationBournemouth, Dorset and Poole Prescribing Forum
SHARED CARE GUIDELINE FOR THE USE OF ATOMOXETINE IN ADULTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER INDICATION Atomoxetine is a non-stimulant non-amphetamine inhibitor of noradrenaline reuptake. It
More informationConduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA)
E102 Conduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA) Patient details Name: Date of birth: NHS number: Contact details Specialist:
More informationSAMPLE. This direction was authorised on 4/5/2007. The direction will be reviewed by 4/5/2009
Patient Group Direction for the Supply and Administration of Flumazenil 100microgram Injection To Patients requiring reversal of oversedation due to midazolam in association withendoscopy attending Endoscopy
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Shared Care Guideline for the prescribing and monitoring of antipsychotics for the treatment of Neurodevelopmental Disorders in children and adolescents. Scope: Version 1 Pennine
More informationPrescribing Framework for Rivastigmine in the Treatment and Management of Dementia
Hull & East Riding Prescribing Committee Prescribing Framework for Rivastigmine in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker)
More informationGREATER MANCHESTER INTERFACE PRESCRIBING GROUP
GREATER MANCHESTER INTERFACE PRESCRIBING GROUP On behalf of the GREATER MANCHESTER MEDICINES MANAGEMENT GROUP SHARED CARE GUIDELINE FOR THE PRESCRIBING OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)
More informationBuccal Midazolam For the treatment of prolonged epileptic seizures, clusters of epileptic seizures and status epilepticus.
Oxfordshire Clinical Commissioning Group, Oxford University Hospitals NHS Trust and Oxfordshire Health NHS Foundation Trust Shared Care Protocol and Information for GPs Buccal Midazolam For the treatment
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
Step 3: GAD with marked functional impairment or that has not improved after step 2 interventionsentions bring together everything NICE says on a topic in an interactive flowchart. are interactive and
More informationPATIENT GROUP DIRECTION PROCEDURE
PATIENT GROUP DIRECTION PROCEDURE Date approved 2 October 2015 Version 3 Approved by Yvette Oade, Chief Medical Officer Procedure Lead Clinical Governance Lead - Medicines Management Procedure Author Karen
More informationSedation Guidelines for Air Ambulance Transfer of Psychiatric Patients
Sedation Guidelines for Air Ambulance Transfer of Psychiatric Patients 1 Determine transfer risks as per BC Ambulance Risk Stratification Tool 2 Determine required sedation level accordingly: RASS Level
More informationTrust Guideline for the Management of Sedation in Painless Imaging Procedures in Children
A clinical guideline recommended for use For Use in: By: For: Division responsible for document: Key words: Children s Day Ward (CDW), Children s Assessment Unit (CAU), Buxton Ward, Radiology. Paediatric
More informationTrust Protocol for the Administration of Intravenous Methylprednisolone for Thyroid Eye Disease A Protocol. The Clinical Investigation Unit (CIU)
A Protocol For Use in: By: For: Division responsible for document: Key words: Name of document author: Job title of document author: Name and job title of document author s Line Manager: Supported by:
More informationRevised Appendix E of the Code of Professional Conduct promulgated in Issue No. 24 of the newsletter of the Medical Council in December 2017
Revised Appendix E of the Code of Professional Conduct promulgated in Issue No. 24 of the newsletter of the Medical Council in December 2017 A. Application of Guidelines Guidelines on Proper Prescription
More informationNational Audit of Dementia
National Audit of Dementia (Care in General Hospitals) Date: December 2010 Preliminary of the Core Audit Commissioned by: Healthcare Quality Improvement Partnership (HQIP) Conducted by: Royal College of
More informationTrust Policy. Title: Sedation Policy for Adult Patients. Key Points
Trust Policy Title: Sedation Policy for Adult Patients Authors: Barry Nicholls, Consultant Anaesthetist & Jon Beard, Chief Pharmacist Policy Lead: Barry Nicholls, Consultant Anaesthetist Ratified by: Policy
More informationSUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS
SUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS Guideline Title Summary of Product Characteristics for Benzodiazepines as Anxiolytics or Hypnotics Legislative basis Directive
More informationPSYCHOTROPIC SOLUTIONS
PSYCHOTROPIC SOLUTIONS A proactive approach to antipsychotic medication management A Quality Use of Medicines initiative by Choice Aged Care Copyright 2018 Hello everyone. Today we will be discussing the
More informationSmoking Cessation Pharmacotherapy Guidelines
Smoking Cessation Pharmacotherapy Guidelines INTRODUCTION This guideline is based on public health guidance 10 Smoking Cessation Services issued by the National Institute for Health and Clinical Excellence
More informationMedicines Protocol RECTAL DIAZEPAM
Medicines Protocol RECTAL DIAZEPAM RECTAL DIAZEPAM v2.0 1/6 Protocol Details Version 2.0 Legal category Staff grades POM Registered Paramedic Registered Nurse Specialist Paramedic (Urgent and Emergency
More informationCHEMOTHERAPY NETWORK GROUP POLICY FOR ADMINISTRATION OF CYTOTOXIC CHEMOTHERAPY
CHEMOTHERAPY NETWORK GROUP POLICY FOR ADMINISTRATION OF CYTOTOXIC CHEMOTHERAPY Version 4.0 March 2016 Review date March 2018 Introduction It is the purpose of this policy to provide clear guidelines that
More informationCare in the Last Days of Life
Care in the Last Days of Life Introduction This guideline is an aid to clinical decision making and good practice in person-centred care for patients who are deteriorating and at risk of dying. The patient
More informationPatient Group Directions Policy
Patient Group Directions Policy Category: Summary: Equality Analysis undertaken: Valid From: Date of Next Review: Approval Date/ Via: Distribution: Related Documents: Author(s): Further Information: This
More informationPSYCHOTROPIC SOLUTIONS
PSYCHOTROPIC SOLUTIONS A proactive approach to antipsychotic medication management A Quality Use of Medicines initiative by Choice Aged Care Copyright 2018 Key Senate Committee Recommendations: All RACF
More informationIndex No: MMG11/1. Version: 1. Date ratified: 12 th November 2013
Index No: Intravenous fluid prescription in children For previously well children aged one month to 16 years (excluding renal, cardiac, diabetic ketoacidosis and acute burns patients) Version: 1 Date ratified:
More informationStaff Immunisation Policy
Policy No: IC05 Version: 8.0 Name of Policy: Staff Immunisation Policy Effective From: 18/08/2015 Date Ratified 15/07/2015 Ratified Infection Prevention & Control Committee Review Date 01/07/2017 Sponsor
More informationBenzodiazepines and Hypnotics
Benzodiazepines and Hypnotics Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review date (when this version goes out of date):
More informationIntegrated Care Pathway (ICP) for the. Management of clozapine INPATIENT INITIATION
Document Reference MM 048 Integrated Care Pathway (ICP) for the Management of clozapine INPATIENT INITIATION Surname Title Address Forenames Date of Birth RT/NHS number Care Co-ordinator GP CS number Consultant
More informationSedative-Hypnotics. Sedative Agents (General Considerations)
Sedative Agents (General Considerations) No best sedative agent Any agent given in sufficient dosage can produce any level of sedation Intravenous dosing is more predictable then intramuscular or oral
More informationPrescribing Framework for Galantamine in the Treatment and Management of Dementia
Hull & East Riding Prescribing Committee Prescribing Framework for Galantamine in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker)
More informationPolicy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04
Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04 Date issued Issue 1 Nov 2018 Planned review Nov 2021 PPT-PGN 18 part of NTW(C)38 Pharmaceutical
More informationOlanzapine Long Acting Injection (LAI) Guideline
Olanzapine Long Acting Injection (LAI) Guideline Guidance and Procedure for the use of Olanzapine Hertfordshire Partnership University NHS Foundation Trust Version: 1.0 Lead Author: Chief Pharmacist Approved
More informationThe Maudsley Prescribing Guidelines in
The Maudsley Prescribing Guidelines in 11th Edition David Taylor Director of Pharmacy and Pathology South London and Maudsley NHS Foundation Trust; Professor King's College London, London, UK Paton Chief
More informationPsychiatric Emergencies and Psychotropic Medication
Psychiatric Emergencies and Psychotropic Medication 15 years old Autistic non-verbal moderate ID Escalating agitated anxious and aggressive behaviour school and home over last 6 months. 180cm, 85kg Two
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationSHARED CARE PROTOCOL FOR THE PRESCRIBING AND MONITORING OF MEDICINES FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)
SHARED CARE PROTOCOL FOR THE PRESCRIBING AND MONITORING OF MEDICINES FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) 1. Introduction This protocol describes how patients prescribed medicines for ADHD
More informationEffective Shared Care Agreement for the treatment of severe motor complications in people with Parkinson Disease with apomorphine (APO-go )
Effective Shared Care Agreement for the treatment of severe motor complications in people with Parkinson Disease with apomorphine (APO-go ) This shared care agreement outlines the ways in which the responsibilities
More informationAppendix 1. Cognitive Impairment and Dementia Service Elm Lodge 4a Marley Close Greenford Middlesex UB6 9UG
Appendix 1 Mr Dwight McKenzie Scrutiny Review Officer Legal and Democratic Services Ealing Council Perceval House 14 16 Uxbridge Road Ealing London W5 2HL Cognitive Impairment and Dementia Service Elm
More informationCase scenarios: Patient Group Directions
Putting NICE guidance into practice Case scenarios: Patient Group Directions Implementing the NICE guidance on Patient Group Directions (MPG2) Published: March 2014 [updated March 2017] These case scenarios
More informationPrescription of High Dose Antipsychotic Medication
Subject (M1) Title Medicine Prescription of High Dose Antipsychotic Medication Manual Mental Health Procedure No M1-P-2-MH Department Pharmacy Distribution All Author Rae McKnight Review 4 Reviewer Jonathan
More information